Embolic Protection Devices Market 2021 - Segments, Trends, Share and Forecast Growth

The Research Report on“Embolic Protection Devices Market by Type (Distal Filter, Distal Occlusion, Proximal Occlusion), Material (Nitinol, Polyurethane), Application (Cardiovascular, Neurovascular, Peripheral), Indication (PCI, SVD, TAVR) – Global Forecast to 2023″ published by MarketsandMarkets™, is projected to reach USD 604.9 Million, at a CAGR of 8.3% during the forecast period.

The growth in this market is mainly attributed to factors such as the rising incidence of cardiovascular and neurovascular diseases, growing funding and investments, launch of technologically advanced embolic protection devices, and the rising demand for minimally invasive procedures.

Research Methodology;

Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary sources; directories; databases such as Hoovers, Bloomberg Businessweek, Factiva, and OneSource, journals and their market revenues were determined through primary and secondary research. Secondary research included the study of the annual and financial reports of top market players, whereas primary research included extensive interviews with the key opinion leaders such as CEOs, directors, and marketing executives. The percentage splits, shares, and breakdowns of the product markets were determined using secondary sources and verified through primary sources. All possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158143803

Embolic Protection Devices Market Segmentation in Detailed:

The neurovascular segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, categorized into cardiovascular, neurovascular, and peripheral vascular diseases. The neurovascular segment is expected to grow at the highest CAGR during the forecast period. The favorable medical reimbursement scenarios for neurovascular procedures in developed countries, increasing awareness about the clinical efficacy of embolic protection devices among neurosurgeons, and the rising adoption of these systems across developing countries (such as China and India) are expected to drive the growth of this application segment during the forecast period.

The percutaneous coronary intervention segment accounted for the largest market share in 2017

On the basis of indication, categorized into percutaneous coronary intervention, transcatheter aortic valve replacement (TAVR), carotid artery diseases, saphenous vein graft disease, and other indications. In 2017, the percutaneous coronary intervention segment accounted for the largest share of the global embolic protection devices market. The large share of this segment can primarily be attributed to the increasing prevalence of CAD and the rising preference for minimally invasive procedures.

Geographical View in-detailed:

North America dominated the embolic protection devices market. The rising geriatric population and prevalence of cardiovascular and neurovascular diseases, increasing adoption of minimally invasive techniques, increasing availability of funding, and the presence of a large number of medical device product manufacturers are driving the growth of the market in North America. However, the APAC is expected to grow at the highest CAGR during the forecast period. The high growth of this segment is attributed to the growing geriatric population, rising prevalence of CVD, increasing number of facilities, and rising healthcare expenditure.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158143803

Global Key Leaders:

The prominent players in the embolic protection devices market are Boston Scientific (US), Medtronic  (Ireland), Abbott (US), Cordis (A Cardinal Health Company) (US), Allium Medical (Israel), Contego Medical (US), W.L. Gore & Associates (US), Silk Road Medical (US), Claret Medical (US), and AngioSlide (Israel).

Cell Harvesting Market - Emerging Industry Trends and Global Future Forecast

The report “Cell Harvesting Market by Type (Manual, Automated), Application (Biopharmaceutical, Stem Cell Research), End User (Biotechnology, Biopharmaceutical Companies, Research Institute), and Region (North America, Europe, APAC, Row) – Global Forecast”, the cell harvesters market is expected to reach USD 324.5 Million, at a CAGR of 8.7%

The Cell harvesting is the process of harvesting cells from the culture media during upstream and downstream bio-processing. Cell harvesters are used extensively for the cell harvesting process and are compatible with a wide range of assays. Rising investments in regenerative medicine and cell-based research, growth of the biotechnology and bio-pharmaceutical industry, and increasing incidence of chronic and infectious diseases are the major factors that are driving the growth of this market.

The objectives of this study are as follows:

• To define, describe, and forecast the cell harvesting market for cell harvesting, on the basis of type, application, end user, and region
• To provide detailed information regarding the major factors influencing growth of the market (drivers, opportunities, and restrains)
• To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders
• To forecast revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=209513544

The manual cell harvesters segment dominated the market.

On the basis of type, the market is segmented into manual and automated cell harvesters. In 2017, the manual cell harvesters segment accounted for the largest share of this market. The high share of the manual harvesters segment can be attributed to their ease of use and low price as compared to automated harvesters.

The biotechnology & biopharmaceutical companies segment dominated the market.

In the end user, the cell harvesting market is segmented into research institutes, biotechnology & biopharmaceutical companies, and other end users. In 2017, the biotechnology & biopharmaceutical companies segment accounted for the largest share of the cell harvesters market. The high share of this segment can be attributed to the high prevalence of chronic diseases. Biotechnology & biopharmaceutical companies conduct R&D activities to develop new products for the treatment of these diseases.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209513544

Geographical View in-detailed:

The global cell harvesting market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). While North America held the largest share of the market in 2017, Asia Pacific is expected to register the highest CAGR during the forecast period. As increasing R&D expenditure helps in the development of new treatment solutions, supportive government policies for stem cell research and increasing public-private initiatives to encourage public adoption of stem cell-based treatment in the Asia Pacific countries are driving the growth of the market in this region.

Global Key Leaders:

Some of the major players operating in the cell harvesting market are PerkinElmer (US), Brandel (US), TOMTEC (US), Cox Scientific (UK), Connectorate (Switzerland), Scinomix (US), ADSTEC (Japan), and Terumo BCT (a part of Terumo Corporation) (Japan).

Antinuclear Antibody Test Market 2021 - Global Growth, Size, Share, Demand, Trends and Forecast

The report “Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) – Forecast”, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the ANA testing market, along with revenue estimates & forecasts and market share analysis.

The Global Antinuclear Antibody Testing Market is expected to reach USD 1,476.1 Million, at a CAGR of 12.4%. The increasing prevalence of autoimmune diseases and increasing healthcare expenditure worldwide are the major factors driving the growth of this market.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=218189007

Market Segmentation in Detailed:

Based on Products, the ANA testing market is segmented into assay kits & reagents, systems, and software & services. The assay kits & reagents segment is expected to account for the largest share of the global market, primarily due to the growing number of reagent rental agreements and increasing prevalence of autoimmune diseases worldwide.

The Antinuclear Antibody Test Market is segmented into five major disease segments, namely, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, and other diseases. Other diseases include Raynaud’s Syndrome, polymyositis, mixed connective tissue disease, drug-induced lupus, and autoimmune hepatitis. The rheumatoid arthritis segment is expected to account for the largest share of this market primarily due to the increasing incidence of rheumatoid arthritis.

Based on techniques, the ANA testing market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market majorly due to the expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring.

Geographical View in-detailed:

The global antinuclear antibody test market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to dominate the global market in the forecast period. However, Asia is expected to witness the highest growth in the coming years, with the growth in this regional segment centered at China, Japan, and India.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218189007

Global Key Leaders:

Key players in the antinuclear antibody test market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).

Bio-Rad Laboratories, Inc. (U.S.) is the third-largest player in the global ANA testing market, with a share of 9.5%. Bio-Rad caters to the life science research and clinical diagnostics market by developing and supplying novel products and services. The company’s product portfolio comprises analysis kits, reagents, and systems for antinuclear antibody testing. It focuses on new product launches and acquisitions as its key growth strategies.

In-depth Analysis of the COVID-19 Impact on Global BRIC Diagnostic Imaging Equipment Market

The report “BRIC Diagnostic Imaging Equipment Market by Modality ((X-Ray Imaging (Digital, Analog), MRI (High & Low Field), CT (Conventional, CBCT), Nuclear Imaging (SPECT, Hybrid PET)), End User (Hospitals, Imaging Centers) – Global Forecast to 2024″, is Diagnostic Imaging Equipment Market projected to reach USD 8.3 billion by 2024 from USD 5.3 billion in 2019, at a CAGR of 9.2% from 2019 to 2024.

The Rapidly growing geriatric population coupled with the subsequent increase in the prevalence of associated diseases and increasing demand for early disease diagnosis are some of the key factors fueling market growth. Moreover, technological advancements in diagnostic imaging modalities and increasing investments, funds, and grants by public-private organizations are anticipated to further drive the growth of the diagnostic imaging market in BRIC countries.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=242

Hospitals were the largest end-user segment in the market in 2018;

On the basis of end users, the hospitals segment commanded the largest share of the BRIC diagnostic imaging equipment market in 2018. The large share of this segment can be attributed to the rising number of diagnostic imaging procedures performed in hospitals, growing inclination toward the automation and digitization of radiology patient workflow, and increasing adoption of minimally invasive procedures.

Geographical View in-detailed:

On the basis of countries, segmented into Brazil, Russia, India, and China. China accounted for the largest share of the BRIC diagnostic imaging equipment market in 2018, followed by India. China has a dynamic and fast-growing healthcare industry with significant government emphasis on the modernization and expansion of the rural healthcare infrastructure. Moreover, rising geriatric population and associated diseases, easy accessibility to diagnostic imaging modalities, and rising adoption of advanced modalities are the key factors fueling the growth of the Chinese market.

Global Key Leaders:

The major players in the market include GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Carestream Health, Inc. (US), Hologic, Inc. (US), Hitachi, Ltd. (Japan), Neusoft Corporation (China), Allengers (India), CURA Healthcare (India), NP JSC Amico (Russia), SONTU Medical Imaging Equipment Co., Ltd. (China), FUJIFILM Holdings Corporation (Japan), and United Imaging Healthcare Co, Ltd. (China), among others.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242

Koninklijke Philips N.V. (Netherlands) held the major share of the BRIC diagnostic imaging equipment market in 2018. As part of its strategy, Philips focuses on product launches and expansions to increase its market share in this highly competitive market. China offers significant opportunities for Philips due to its large patient pool and developing healthcare infrastructure. In order to deliver technologically advanced solutions at economical prices, the company established an AI lab in Shanghai, China. The company has also entered into partnerships & collaborations with various companies and organizations in the country to enhance its market share.

Siemens Healthineers (Germany) held the second position in the BRIC diagnostic imaging equipment market in 2018. The company has a significant presence in BRIC nations and offers a number of modalities in the diagnostic imaging market. With a robust product portfolio, Siemens Healthineers holds a strong position in the diagnostic imaging market. To maintain its competitive position, the company focuses on new product launches and expansions as key organic growth strategies. In 2018, the company introduced the Mammomat Revelation Mammography System and NX Series Ultrasound machines in India. These developments have helped the company to expand its customer base and strengthen its geographical footprint across the globe. Siemens is considered as one of the key players in the global market due to its vast product portfolio and strong distribution channels. Moreover, the company invested around USD 6.6 billion, USD 5.7 billion, and USD 5.3 billion in R&D during 2018, 2017, and 2016, respectively.

Thyroid Function Test Market Size, Share, Growth, Trend and Forecast 2022

The report “Thyroid Function Test Market by Type (TSH Tests, T4 Tests, T3 Tests), End User (Hospitals, Diagnostic Laboratories, Research Laboratories & Institutes), and Region (North America, Europe, APAC, LATAM, and MEA) – Global Forecast”, is expected to reach USD 1.68 Billion, at a CAGR of 5.9%.

The Growth of the market can primarily be attributed to the increasing incidence of thyroid disorders, increasing awareness about thyroid disorders, increasing prevalence of lifestyle diseases, rising geriatric population, and increasing consumption of alcohol & tobacco. Growth opportunities in emerging Asia Pacific countries to provide lucrative growth opportunities for players in the thyroid function tests market.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=85085049

Objectives of the Study:

• To define, describe, segment, and forecast the global market by type, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
• To analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To profile the key players and comprehensively analyze their product portfolios, market shares, and core competencies in the global thyroid function tests market

The TSH tests segment is expected to account for the largest share of the market.

On the basis of type, segmented into TSH tests, T4 tests, T3 tests, and other tests. In 2017, the TSH tests segment is estimated to account for the largest share of the thyroid function tests market. The large share rate of this segment can be attributed to the fact that TSH tests are initially prescribed by physicians to majority of patients (for the assessment of thyroid gland functioning) showing symptoms of thyroid disorders.

Geographical View in-detailed:

The North American market is expected to account for the largest share of the global thyroid function test market due to the presence of an advanced healthcare infrastructure in North American countries such as the US and Canada. However, the Asia Pacific market is expected to grow at the highest CAGR in the forecast period. This growth can be attributed to factors such as the presence of a large target patient population, increasing disposable income of the middle-class population, and improving healthcare infrastructure in emerging countries such as China and India.

Global Key Leaders:

The prominent players in the global thyroid function test market include Thermo Fisher (US), Abbott (US), Roche (Switzerland), DiaSorin (Italy), Danaher (US), Kronus (US), Merck (Germany), Cortez Diagnostics (US), bioMérieux (France), Qualigen (US), and Autobio Diagnostics (China).

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=85085049

COVID-19 Impact on Vaccines and Drugs Market - Global Key Players, Trends, Industry Size & Forecast

The report “COVID-19 Impact on Vaccines and Drugs Market – Global Forecast to 2025″ the COVID-19 impact on the global vaccines market size is estimated at USD 2,273 million in 2022 and projected to reach USD 1,401 million by 2025, resulting in a CAGR of -14.9%. On the other hand, the COVID-19 impact on the global drugs market size is anticipated at 165 million in 2020 and estimated to reach USD 2 million by 2025, at a CAGR of -57.8%.

The growth of the COVID vaccines market is attributed majorly to the increasing number of people infected with coronavirus and growing funding for vaccine development. The growth of the COVID drugs market is primarily attributed to use of repurposed drugs for compassionate use, the emergence of alternate therapies, such as convalescent plasma therapy which were earlier used for treating epidemic diseases such as SARS, MERS, and H1N1, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=112248051

Funding from global governments and foundations is promoting the growth of the market;

Incentives are needed to engage manufacturers for the large-scale capacity to guarantee sufficient production of SARS-CoV-2 vaccines. In line with this, various global organizations have come forward to expedite the process, such as Gavi, CEPI, and WHO. However, considering the pandemic scenario of COVID-19, much stronger initiatives are required.

In April 2020, the Bill and Melinda Gates Foundation announced plans to help fund factories for seven promising vaccines, even before seeing conclusive data. The foundation aims to help scale up manufacturing during testing, rather than after the vaccines have passed the trials.

Besides the most promising Moderna program, several other big pharma companies are involved in COVID-19 vaccine work. Johnson & Johnson has pledged a manufacturing scale-up to 1 billion doses for its federally partnered program. Meanwhile, Sanofi has two partnerships underway—one with the federal government and another with Translate Bio.

Some of the major players in the COVID-19 vaccines market include Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Janssen Pharmaceuticals, Inc. (Belgium) among others.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=112248051

Some of the key players are collaborating to expedite the vaccines and drug development. For instance, In February 2020, Janssen announced that it would work collaboratively with laboratories to screen antiviral therapies. Janssen already donated several doses of PREZCOBIX (for research use) to the Shanghai Public Health Clinical Center, Zhongnan Hospital of the Wuhan University, and the Chinese Center for Disease Control and Prevention. Big players in vaccines have also entered the race of launching vaccines targeting COVID-19, such as GSK and Sanofi. Sanofi and GSK are coming together to work on a Covid-19 vaccine, which, if it passes clinical trials, will become available in the next 12- 18 months’ timeline.

Clinical Risk Grouping Solutions Market - Growth Factors Analysis, Share and Forecast

The report “Clinical Risk Grouping Solutions Market by Product (Scorecard & Visualization Tools, Dashboard Analytics, Risk Reporting), Deployment (Private Cloud, Public Cloud, Hybrid Cloud), End-User and Region – Global Forecast to 2024″, projected to reach USD 829 million by 2024 from USD 427 million in 2019, growing at a CAGR of 14.2%.

The Factors such as increasing focus on risk management solutions in the healthcare industry and rising implementation of big data solutions are driving the market for clinical risk grouping solutions. Increasing instances of physician burnout due to clinical documentation and a shift towards software based on AI and machine learning also present significant growth opportunities for market players.

Clinical Risk Grouping Solutions Market Share Estimation;

The market shares for clinical risk grouping solutions companies was arrived at after detailed assessment of their revenues from the clinical risk grouping solutions business by secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases revenue share was arrived at after detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews.

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=72780829

Based on the product, segmented into scorecard & visualization tools, dashboard analytics, and risk reporting solutions. The scorecard & visualization tools segment accounted for the largest share of the clinical risk grouping solutions market in 2018. The large share of this segment can be attributed to the high usage of risk attributing and risk scoring usage in clinical risk grouping solutions.

Geographical View in-detailed:

The clinical risk grouping software market in North America is driven by the growing focus on quality care, increasing focus on population health management, and cost containment in the healthcare industry. Also, a highly suitable healthcare IT infrastructure and rising adoption of clinical risk grouping solutions by healthcare payers in the region are supporting the growth of clinical risk grouping solutions in this region.

Global Key Leaders:

3M Corporation (US) and Optum, Inc. (US) dominated the global clinical risk grouping solutions market in 2018. The prominent players in the global market are Cerner Corporation (US), Conduent Inc. (US), Nuance Communications (US), Health Catalyst (US), HBI Solutions (US), Johns Hopkins University (US), Lightbeam Health Solutions (US), Dynamic Healthcare Systems (US), 4S Information Systems (US), Evolent Health (US), and PeraHealth (US).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72780829

3M Corporation (US) is a diversified company with a wide range of product offerings across different industries. The company has more than 30 years of experience in developing solutions for classification, grouping, and reimbursement calculation systems for inpatient, outpatient, and professional settings. This platform of innovative services, along with a comprehensive product portfolio for clinical risk grouping makes it a leading market player in the clinical risk grouping solutions market. 3M relies on product innovation internally. For instance, the company’s R&D expenditure in 2018 was USD 1.82 billion, which accounts for 6% of its total revenue.

Optum, Inc. (US) provides a variety of healthcare IT solutions such as EHR/EMR solutions, mHealth solutions & services, ePrescribing, healthcare asset management solutions for pharmacies, revenue cycle management solutions and facilitates the complete lifecycle of its patient access, clinical documentation process, claims, eliminating multiple systems, and inefficient manual mid-revenue cycle processes. It also offers healthcare IT solutions and services to help care providers and health care payers efficiently improve their clinical performance, quality of care, and establish consumer engagement.

Cell Signaling Market Size, Share on Global Analysis Report

The report “Cell Signaling Market by Type (Endocrine, Paracrine), Pathway (Akt, AMPK, Hedgehog, Notch), Product (Consumables, Instruments), Technology (Flow Cytometry, ELISA, Mass Spectrometry) & Application (Research, Cancer, Immunology) – Global Forecast “, is expected to reach $3.51 billion, at a CAGR of 6.8%

The term “cell signaling” is used to define the complex interactive system of signals that regulates and mediate various cellular responses in the human body.

Cell signaling is used to study signaling pathways of cells in drug discovery and therapeutic development, to distinguish drug resistance patterns in cancerous cells. It also identifies the major signaling pathways impacted by specific drug treatments. Cell signaling pathways—also called signal transduction pathways—act as connecting links between environmental stimuli and the corresponding cellular response. These signaling pathways mainly consist of proteins that can interact, move to specific locations, or be modified.

Don’t miss out on business opportunities in “Cell Signaling Market”. Speak to Our Analyst and gain crucial industry insights that will help your business growth:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=80206120

Availability of funding cell based research is key driver for the global cell signalling market;

Governments of various countries are promoting and supporting cell-based research activities such as cell signalling, single-cell analysis, and stem cell research. A large portion of the funding from governments is provided to academic research societies to promote cell-based research, which helps in the evaluation of diagnostic and therapeutic applications of various types of cells in the management of chronic and infectious diseases. By driving research into the application and end-user industries for cell analysis, the availability of support plays a significant role in aiding market growth.

Market Segmentation in Detailed:

Based on product, segmented into consumables and instruments. The cell signaling consumables segment is estimated to account for the largest share of the cell signaling market. The increasing number of cell signaling research activities and rising incidence of chronic diseases are some of the major factors contributing to the segments large market share.

On the basis of technology, segmented into enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), microscopy, flow cytometry, western blotting, mass spectrometry, and other technologies (immunofluorescence and immunoprecipitation). The microscopy segment is estimated to account for the largest share.

Geographical View in-detailed:

The Cell Signaling Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to account for the largest share of the market. Growth in this regional segment is driven by the growth in geriatric population, rising incidence of chronic diseases, and improved life science research infrastructure in the region.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80206120

Global Key Leaders:

The key players in the cell signaling market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.) (a subsidiary of Danaher Corporation), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer Inc. (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Abcam plc (U.K.), Miltenyi Biotec (Germany), Full Moon BioSystems, Inc. (U.S.)

Viral Inactivation Market Size, Share, Outlook, Industry Analysis Report 2021

The report “Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) – Global Forecast”, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global viral inactivation market along with the estimates and forecasts of the revenue and market share analysis.

Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. The major drivers for the market are rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in life sciences industry. Increasing number of new drug launches, rise in chronic disease burden, and increasing government support for the pharmaceutical and biotechnology industries will also aid the growth of this market.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121427017

Viral Inactivation Market Segmentation in Detailed:

By method, the market is divided into solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light. Of these, the solvent detergent method segment accounted for the largest share of the global viral inactivation market.

By application segments included in this report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics. Of these the vaccines and therapeutics application hold the highest share.

By end user, segmented into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users. Other end user segment primarily includes cell banks, small cell culture laboratories and consultants, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, and media/sera manufacturers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121427017

Geographical View in-detailed:

The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). The North America segment is further divided into Canada and the U.S. Asia segment is further divided into China, Japan, India, and Rest of Asia.

Global Key Leaders:

Major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).

There is a high degree of consolidation in the viral inactivation market, with few large players dominating the market. High degree of consolidation is major barriers for new entrants in this market. Small and medium-sized players account for a small share of the market and their business interests remain concentrated in local markets across emerging geographies.